Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02545504 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02545504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02545504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
October 13, 2015
Completion date
May 15, 2019
Enrollment
432 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma